Abstract:9068 Background: AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs. However, acquired resistance to AZD9291 is inevitable. In this study, we retrospectively analyzed mechanisms of acquired resistance to AZD9291 in advanced NSCLC. Methods: A total of 293 advanced lung adenocarcinoma patients with signs of AZD9291 resistance were enrolled in the study from January to October 2017. Tissue biopsy was the first choice for mutation profiling, and ctDNA testing was used as an alternative. All samples were analyzed using next-generation sequencing based ER-Seq method, which enables simultaneously assess single-nucleotide variants, insertions/deletions, rearrangements, and somatic copy-number alterations across at least 59 genes (59-1021). Results: At resistance, 3 molecular subtypes emerged: 66 cases (22.5%) lost original EGFR activating mutation and T790M mutation; 130 cases (44.4%) lost the T790M mutation despite detecting of the underlying EGFR activating mutation; 97 cases (33.1%) maintained both EGFR activating mutation and T790M mutation. Known resistance mechanisms detected in 11/66 (16.7%), 56/130 (43.1%), 62/97 (63.9%) cases respectively for all the 3 subtypes. The most frequently known mechanism was EGFR C797S which was identified in 60 cases, while EGFR L792H/V, G796S, L718Q/V, G719A, and E709K were in 27 cases. Activating mutations of PI3K-AKT-mTOR signaling, amplification of the MET, activating mutation / amplification of ERBB2, ALK/ROS1/RET fusion, activating mutation of BRAF, or KRAS were identified in 37, 16, 14, 9, 8, 5 patients respectively. Moreover, 24 cases had Rb1 loss of function mutation. Co-occurrence of resistance mechanisms were observed in 31 patients. Conclusions: There was a high frequency of inter and intra-patient heterogeneity of resistance mechanisms after AZD9291 therapy. Comprehensive NGS analysis may facilitate the broad exploration of potential resistance mechanisms.

Structural Basis of AZD9291 Selectivity for EGFR T790M

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds

Supplementary Figure 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

Structural basis for the selectivity of 3rd generation EGFR inhibitors: a molecular dynamics study

Structural Pharmacological Studies on EGFR T790M/C797S

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Design, Synthesis, SAR Discussion, in Vitro and in Vivo Evaluation of Novel Selective EGFR Modulator to Inhibit L858R/T790M Double Mutants

Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Structural pharmacological studies on EGFR T790M/C797S.

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Supplementary Table 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Crystal Structure of EGFR T790M/C797S/V948R in Complex with EAI045

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Structural Basis of Mutant-Selectivity and Drug-Resistance Related to CO-1686.

Supplementary Figure 6 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.

Structural insights into drug development strategy targeting EGFR T790M/C797S

Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation

Next Generation Sequencing (NGS) Based Mutation Profiling and Heterogeneity of Resistance Mechanisms to AZD9291.